Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …

Accurate control of gene expression is essential for normal development and dysregulation
of transcription underpins cancer onset and progression. Similar to cell cycle regulation …

Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …

Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …

Cancers display significant heterogeneity with respect to tissue of origin, driver mutations,
and other features of the surrounding tissue. It is likely that individual tumors engage …

The neuroendocrine carcinoma of the gastrointestinal system (GIS-NEC) is a rare but highly
malignant neoplasm. We analyzed 115 cases using whole-genome/exome sequencing …

Distilling biologically meaningful information from cancer genome sequencing data requires
comprehensive identification of somatic alterations using rigorous computational methods …

Metastatic prostate cancer remains a major clinical challenge and metastatic lesions are
highly heterogeneous and difficult to biopsy. Liquid biopsy provides opportunities to gain …

Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically
resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we …

Localized prostate cancer shows great clinical, genetic and environmental heterogeneity;
however, prostate cancer treatment is currently guided solely by clinical staging, serum PSA …